{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:02:29Z","timestamp":1765278149119,"version":"3.46.0"},"reference-count":18,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2019-0031_s_001_w2aab3b7c26b1b6b1aab1c15b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The body surface area (BSA) is taken as a measure for the effective contact area for dosing in hyperthermic intraperitoneal chemotherapy (HIPEC). Currently, the pharmacokinetic effect of the reduced peritoneal surface area (PSA) after cytoreductive surgery (CRS) during HIPEC remains unclear. Here a proprietary software solution (PEritoneal SUrface CAlculator (PESUCA)) to quantify the resected PSA in patients with peritoneal surface malignancies (PSM) undergoing CRS and HIPEC is presented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0031_s_002_w2aab3b7c26b1b6b1aab1c15b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The PESUCA tool was programmed as a desktop and online software solution. The applicability was evaluated in 36 patients. The programming-algorithm is briefly summarized as follows: (1) calculation of BSA, (2) correlation to PSA, (3) calculation of the relative proportion of 40 different anatomical regions to total PSA before CRS, (4) instantaneous input of each resected proportion in the 40 anatomical regions during CRS, and (5) determination of the resected and remaining PSA after CRS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0031_s_003_w2aab3b7c26b1b6b1aab1c15b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The proof of concept revealed a mean PSA of all patients before CRS of 18,741\u2009\u00b1\u2009321 cm\n                      <jats:sup>2<\/jats:sup>\n                      compared to 13,611\u2009\u00b1\u2009485 cm\n                      <jats:sup>2<\/jats:sup>\n                      after CRS (p&lt;0.0001). Patients\u2019 supramesocolic and inframesocolic visceral and parietal peritoneal area before and after CRS procedure were quantitatively determined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0031_s_004_w2aab3b7c26b1b6b1aab1c15b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Here the first tool that enables detailed PSA quantification in patients with PSM undergoing CRS is presented. This makes the software a valuable contribution to ensue more accurate assessment and improved comparability of peritoneal disease extent. Furthermore, after external validation, PESUCA could be the basis for dose adjustment of intraperitoneal chemotherapy regimens based on the remaining PSA after CRS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2019-0031","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T04:03:04Z","timestamp":1582776184000},"source":"Crossref","is-referenced-by-count":1,"title":["The PEritoneal SUrface CAlculator (PESUCA): A new tool to quantify the resected peritoneal surface area after cytoreductive surgery"],"prefix":"10.1515","volume":"5","author":[{"given":"Philipp","family":"Schredl","sequence":"first","affiliation":[{"name":"Department of Surgery , Paracelsus Medical University, Salzburger Landeskliniken (SALK) , M\u00fcllner Hauptstra\u00dfe 48 , Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Philipp","family":"Ramspott","sequence":"additional","affiliation":[{"name":"Department of Surgery , Paracelsus Medical University, Salzburger Landeskliniken (SALK) , M\u00fcllner Hauptstra\u00dfe 48 , Salzburg , Austria"},{"name":"Department of Gynecology and Gynecologic Oncology , Kliniken Essen-Mitte , Henricistra\u00dfe 92, Essen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Neureiter","sequence":"additional","affiliation":[{"name":"Institute of Pathology , Paracelsus Medical University, Salzburger Landeskliniken (SALK) , M\u00fcllner Hauptstr. 48 , Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Emmanuel","sequence":"additional","affiliation":[{"name":"Department of Surgery , Paracelsus Medical University, Salzburger Landeskliniken (SALK) , M\u00fcllner Hauptstra\u00dfe 48 , Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarkan","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"Department of Surgery , Paracelsus Medical University, Salzburger Landeskliniken (SALK) , M\u00fcllner Hauptstra\u00dfe 48 , Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"key":"2025120909224054783_j_pp-2019-0031_ref_001_w2aab3b7c26b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Jung H. Interaction of thermotolerance and thermosensitization induced in CHO cells by combined hyperthermic treatments at 40 and 43 degrees C. Radiat Res 1982;91:433\u201346.","DOI":"10.2307\/3575883"},{"key":"2025120909224054783_j_pp-2019-0031_ref_002_w2aab3b7c26b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Lagast N, Carlier C, Ceelen WP. Pharmacokinetics and tissue transport of intraperitoneal chemotherapy. Surg Oncol Clin N Am 2018;27:477\u201394.","DOI":"10.1016\/j.soc.2018.02.003"},{"key":"2025120909224054783_j_pp-2019-0031_ref_003_w2aab3b7c26b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol 2018;36:LBA3503.","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503"},{"key":"2025120909224054783_j_pp-2019-0031_ref_004_w2aab3b7c26b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HW, Hermans RH, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378:230\u201340.","DOI":"10.1056\/NEJMoa1708618"},{"key":"2025120909224054783_j_pp-2019-0031_ref_005_w2aab3b7c26b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Kusamura S, Dominique E, Baratti D, Younan R, Deraco M. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol 2008;98:247\u201352.","DOI":"10.1002\/jso.21051"},{"key":"2025120909224054783_j_pp-2019-0031_ref_006_w2aab3b7c26b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Helderman R, Loke DR, Kok HP, Oei AL, Tanis PJ, Franken N, et al. Variation in clinical application of hyperthermic intraperitoneal chemotherapy: a review. Cancers (Basel) 2019;11.","DOI":"10.3390\/cancers11010078"},{"key":"2025120909224054783_j_pp-2019-0031_ref_007_w2aab3b7c26b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Lemoine L, Sugarbaker P, Van der Speeten K. Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. Int J Hyperthermia 2017;33:582\u201392.","DOI":"10.1080\/02656736.2017.1291999"},{"key":"2025120909224054783_j_pp-2019-0031_ref_008_w2aab3b7c26b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Ceelen Wim P, Levine E. Intraperitoneal cancer therapy: principles and practice. Boca Raton: CRC Press, 2015.","DOI":"10.1201\/b19409"},{"key":"2025120909224054783_j_pp-2019-0031_ref_009_w2aab3b7c26b1b6b1ab2b2b9Aa","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1\u201311."},{"key":"2025120909224054783_j_pp-2019-0031_ref_010_w2aab3b7c26b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Albanese AM, Albanese EF, Mino JH, Gomez E, Gomez M, Zandomeni M, et al. Peritoneal surface area: measurements of 40 structures covered by peritoneum: correlation between total peritoneal surface area and the surface calculated by formulas. Surg Radiol Anat 2009;31:369\u201377.","DOI":"10.1007\/s00276-008-0456-9"},{"key":"2025120909224054783_j_pp-2019-0031_ref_011_w2aab3b7c26b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"DuBois D. A formula to estimate the approximate surface area if height and body mass be known. Arch Intern Med 1916;17:863\u201371.","DOI":"10.1001\/archinte.1916.00080130010002"},{"key":"2025120909224054783_j_pp-2019-0031_ref_012_w2aab3b7c26b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27:681\u20135.","DOI":"10.1200\/JCO.2008.19.7160"},{"key":"2025120909224054783_j_pp-2019-0031_ref_013_w2aab3b7c26b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426\u201332.","DOI":"10.1245\/s10434-008-9966-2"},{"key":"2025120909224054783_j_pp-2019-0031_ref_014_w2aab3b7c26b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Yurttas C, Hoffmann G, Tolios A, Haen SP, Schwab M, Konigsrainer I, et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer. J Clin Med 2018;7.","DOI":"10.3390\/jcm7120567"},{"key":"2025120909224054783_j_pp-2019-0031_ref_015_w2aab3b7c26b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solutionin patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol 2006;57:703\u20138.","DOI":"10.1007\/s00280-005-0074-8"},{"key":"2025120909224054783_j_pp-2019-0031_ref_016_w2aab3b7c26b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Lemoine L, Thijssen E, Carleer R, Geboers K, Sugarbaker P, van der Speeten K. Body surface area-based vs concentration-based perioperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal surface malignancy treatment: COBOX trial. J Surg Oncol 2019;119:999\u20131010.","DOI":"10.1002\/jso.25437"},{"key":"2025120909224054783_j_pp-2019-0031_ref_017_w2aab3b7c26b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"de Lima Vazquez V, Stuart OA, Mohamed F, Sugarbaker PH. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol 2003;52:108\u201312.","DOI":"10.1007\/s00280-003-0626-8"},{"key":"2025120909224054783_j_pp-2019-0031_ref_018_w2aab3b7c26b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH, Van der Speeten K, Anthony Stuart O, Chang D. Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis. Eur J Surg Oncol 2011;37:719\u201326.","DOI":"10.1016\/j.ejso.2011.04.007"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/5\/1\/article-20190031.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0031\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0031\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:58:28Z","timestamp":1765277908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0031\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,26]]},"published-print":{"date-parts":[[2020,3,26]]}},"alternative-id":["10.1515\/pp-2019-0031"],"URL":"https:\/\/doi.org\/10.1515\/pp-2019-0031","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"type":"electronic","value":"2364-768X"},{"type":"print","value":"2364-7671"}],"subject":[],"published":{"date-parts":[[2020,2,26]]},"article-number":"20190031"}}